 Pharmacogenomic Testing
"Pharmacogenomic Testing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The detection of genetic variability (e.g., PHARMACOGENOMIC VARIANTS) relevant to PHARMACOGENETICS and PRECISION MEDICINE. The purpose of such genetic testing is to help determine the most effective treatment options and their optimum dosages with least potential risks for DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS.
| Descriptor ID |
D000071185
|
| MeSH Number(s) |
E01.370.225.562.500 E05.200.562.500 E05.393.435.500 N02.421.308.430.500 N02.421.726.233.221.500
|
| Concept/Terms |
Pharmacogenomic Testing- Pharmacogenomic Testing
- Pharmacogenomic Testings
- Pharmacogenomic Screening
- Pharmacogenomic Screenings
- Pharmacogenetic Screening
- Pharmacogenetic Screenings
- Pharmacogenetic Testing
- Pharmacogenetic Testings
Pharmacogenomic Analysis- Pharmacogenomic Analysis
- Pharmacogenomic Analyses
- Pharmacogenetic Study
- Pharmacogenetic Studies
- Studies, Pharmacogenetic
- Pharmacogenetic Analysis
- Pharmacogenetic Analyses
- Pharmacogenomic Study
- Pharmacogenomic Studies
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Testing".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Testing".
This graph shows the total number of publications written about "Pharmacogenomic Testing" by people in this website by year, and whether "Pharmacogenomic Testing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 2 | 3 | | 2019 | 1 | 4 | 5 | | 2020 | 3 | 2 | 5 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacogenomic Testing" by people in Profiles.
-
Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021 07; 110(1):179-188.
-
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
-
Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR. CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. Am Heart J. 2020 11; 229:118-120.
-
Deininger KM, Tsunoda SM, Hirsch JD, Anderson H, Lee YM, McIlvennan CK, Page RL, Tran JN, Aquilante CL. National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation. Clin Transplant. 2020 10; 34(10):e14037.
-
Liko I, Lai E, Griffin RJ, Aquilante CL, Lee YM. Patients' Perspectives on Psychiatric Pharmacogenetic Testing. Pharmacopsychiatry. 2020 Nov; 53(6):256-261.
-
Kisor DF, Monte AA, Müller DJ. Pharmacogenetic associations and evidence-based pharmacogenomics guidelines: supporting label and off-label use of drug-gene interaction data. Pharmacogenomics. 2020 05; 21(7):427-430.
-
Anderson HD, Crooks KR, Kao DP, Aquilante CL. The landscape of pharmacogenetic testing in a US managed care population. Genet Med. 2020 07; 22(7):1247-1253.
-
Deininger KM, Tran JN, Tsunoda SM, Young GK, Lee YM, Anderson HD, Page Ii RL, Hirsch JD, Aquilante CL. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation. Pharmacogenomics. 2019 12; 20(18):1291-1302.
-
Dalton R, Lee SB, Claw KG, Prasad B, Phillips BR, Shen DD, Wong LH, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, Gaedigk A, Thummel KE, Woodahl EL. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity. Clin Transl Sci. 2020 01; 13(1):147-156.
-
Sucharov CC, Nakano SJ, Slavov D, Schwisow JA, Rodriguez E, Nunley K, Medway A, Stafford N, Nelson P, McKinsey TA, Movsesian M, Minobe W, Carroll IA, Taylor MRG, Bristow MR. A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. J Am Coll Cardiol. 2019 03 19; 73(10):1173-1184.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|